Bill Gadless

𝗪𝗵𝘆 𝗮𝗿𝗲 𝘄𝗲 𝘀𝗼 𝘀𝗰𝗮𝗿𝗲𝗱 𝘁𝗼 𝘀𝗼𝘂𝗻𝗱 𝗰𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝘁? Most science founders I meet have a weird relationship with marketing. They act like "selling" is a dirty word. They worry that if they speak too loudly, they’ll look like they’re hyping vaporware. They think "serious" science has to be dry, dense, and boring. 𝗦𝗼 𝘁𝗵𝗲𝘆 𝗵𝗶𝗱𝗲. They hide behind 40-slide decks cluttered with data. They hide behind acronyms. They whisper their value prop because they’re terrified of being seen as "commercial." Here’s the reality check: Quiet science doesn’t get funded. It doesn’t get partnered. And it definitely doesn’t get to the patient. If you’ve truly got the goods, being "modest" isn’t a virtue. It’s a liability. The disease you are fighting isn't being polite. It isn't waiting for investors to read between the lines or for the market to "eventually" figure out why you matter. 𝗦𝘁𝗼𝗽 𝗮𝗽𝗼𝗹𝗼𝗴𝗶𝘇𝗶𝗻𝗴 𝗳𝗼𝗿 𝘀𝗲𝗹𝗹𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝘃𝗶𝘀𝗶𝗼𝗻. If the science is real, you have a duty to make sure the world hears it. 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗲 𝗵𝗮𝗿𝗱𝗲𝗿. 𝗧𝗲𝗹𝗹 𝘆𝗼𝘂𝗿 𝘀𝘁𝗼𝗿𝘆 𝗹𝗼𝘂𝗱𝗲𝗿. 𝗢𝗵, 𝗮𝗻𝗱 𝗙 𝗰𝗮𝗻𝗰𝗲𝗿.

𝗪𝗵𝘆 𝗺𝘆 𝗰𝗮𝗻𝗰𝗲𝗿 𝘄𝗶𝗹𝗹 𝘀𝗮𝘃𝗲 𝗹𝗶𝘃𝗲𝘀. I was diagnosed with stage 3 esophageal cancer in October 2024. Yes, this is personal. But this series isn’t about my story. It’s about what became painfully clear the moment I became a patient. 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗲𝘅𝗶𝘀𝘁 𝘁𝗵𝗮𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗰𝗮𝗻’𝘁 𝗳𝗶𝗻𝗱. Trials struggle to enroll while people search for options. Life-saving innovation sits in pipelines, decks, and internal conversations - moving slower than disease ever will. 𝗙𝗿𝗼𝗺 𝘁𝗵𝗲 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗯𝗲𝗱, 𝘂𝗿𝗴𝗲𝗻𝗰𝘆 𝗳𝗲𝗲𝗹𝘀 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁. Language matters more. Silence gets dangerous. I’m launching this new series - Why My Cancer Will Save Lives - to talk about that gap. And why better storytelling closes it. Lives don’t move at corporate speed.

“𝗧𝗵𝗮𝘁’𝘀 𝗺𝘆 𝘀𝗼𝗻,” 𝘀𝗵𝗲 𝘀𝗮𝗶𝗱. Her child’s heart is still beating - inside a 14-year-old boy who’s alive because of it. 💔❤️

#𝗝𝗣𝗠𝟮𝟲: 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 𝗮𝗻𝗱 𝗡𝘃𝗶𝗱𝗶𝗮 𝗷𝘂𝘀𝘁 𝗹𝗼𝗰𝗸𝗲𝗱 𝗶𝗻 𝗮 $𝟭𝗕 𝗔𝗜 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 - 𝗮𝗻𝗱 𝗶𝘁 𝘀𝗮𝘆𝘀 𝗮 𝗹𝗼𝘁 𝗮𝗯𝗼𝘂𝘁 𝘄𝗵𝗲𝗿𝗲 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗶𝘀 𝗵𝗲𝗮𝗱𝗲𝗱. This wasn’t a fluffy “AI will change everything” moment on a JPM stage. It was two CEOs admitting how fast the ground has shifted. Jensen Huang talking about AI accelerating a million-fold. David Ricks saying speed - not ideas - is now the real competitive edge. Lilly is doing more than dabbling. Between Nvidia, Benchling, Chai, Schrödinger, OpenAI … this is a full-stack AI strategy. Data. Models. Compute. Talent. The signal is clear: future blockbusters won’t come from better PowerPoints. They’ll come from companies that build the machine to discover faster than everyone else. #ai #drugdevelopment #tech #bigtech #pharma #pharmaceuticals #biotech #biopharma #nvidia #elililly #lilly #drugdiscovery

The world doesn’t produce enough Tim Tebows.

It’s been a long road of chemo and a transplant, but today made it all worth it: He is officially heading home cancer-free. ❤️

𝗧𝗵𝗲 𝗺𝗮𝗻 𝘀𝗼 𝗺𝗮𝗻𝘆 𝗼𝗳 𝘂𝘀 𝗮𝘀𝗽𝗶𝗿𝗲 𝘁𝗼 𝗯𝗲. Today, we celebrate Christian Nolen’s 13th anniversary at emagine. Christian’s journey is the perfect example of growth: • Started as a Web Developer • Promoted to Technical Director • Now runs the show as EVP of Operations Overseeing operations at the volume we handle is no small feat. It requires precision, but more importantly, it requires composure. Christian has an uncanny ability to stay cool and level-headed regardless of the chaos around him. He is a brilliant executive, a devoted husband, a proud father of two boys, and someone I’m honored to call a friend. Ask anyone on his team, and they will tell you the same thing: We can all learn from Christian. Happy 13th, Christian. Thank you for everything you do.

𝗜 𝘁𝗵𝗼𝘂𝗴𝗵𝘁 𝗜 𝗸𝗻𝗲𝘄 𝘁𝗵𝗲 "𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗝𝗼𝘂𝗿𝗻𝗲𝘆." 𝗧𝗵𝗲𝗻 𝗜 𝗵𝗮𝗱 𝘁𝗼 𝘄𝗮𝗹𝗸 𝗶𝘁. For years, I treated the patient journey like a funnel - a slide in a deck, a conversion strategy. Then came my diagnosis. Suddenly, the funnel wasn’t abstract. It was 3 AM anxiety. It was decoding complex jargon while terrified. It was the desperate wait for a solution. Cancer didn't just change my life; it completely rewired how I view my job. Here is the reality: - Time is the only currency. Delays don't just lose revenue; they cost families time. - Marketing is access. If a patient can’t find, afford, or understand the science, it doesn't exist. - Empathy > Buzzwords. Patients don't want "innovative solutions." They want to know if they’ll see their kid graduate. This experience lit a fire under my creativity. I’m not just chasing KPIs anymore. I’m fueled by a need to get science to patients faster and more economically. My creativity is now a survival mechanism - for me, and for the millions walking this path. Let’s stop marketing at patients and start fighting for them.

𝗬𝗼𝘂𝗿 𝗽𝗶𝘁𝗰𝗵 𝗱𝗲𝗰𝗸 𝗳𝗼𝗿 𝗝𝗣𝗠 𝟮𝟬𝟮𝟲 𝗶𝘀𝗻’𝘁 𝗮 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗳𝗮𝗶𝗿 𝗽𝗼𝘀𝘁𝗲𝗿 - 𝗶𝘁’𝘀 𝗮 𝗰𝗹𝗲𝗮𝗿, 𝗰𝗼𝗻𝗰𝗶𝘀𝗲 𝗲𝘅𝗶𝘁 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆. Everyone has good data. Everyone has a breakthrough. If you're heading to San Francisco, you need to remember the investors' core mission: return on capital. They don't have time to wade through your 80-slide deep dive. Your 30-minute speed date needs to hit the essentials: clear regulatory path, commercial viability, and a team that can execute. Show them how the science translates directly into dollars and impact. That's how you get funded.

Can’t wait to get back on camera. The energy in life sciences right now is unreal. After a couple of quiet, even lame years, the sector finally feels alive again - innovation, funding, new stories worth shouting about. And I’m itching to be part of that conversation - through high-energy, straight-talk video content like I used to do. But here’s the truth: I’m still recovering from surgery. My energy’s limited, my strength’s not all there, and yeah… I’m not feeling great about how I look on camera right now. Still - the ideas are flowing. The fire’s back. And the moment I’ve got the energy to match it, I’m hitting record. ⏺️ I can’t wait to talk with all of you again - for real, face-to-face (well, screen-to-screen). #biotech #pharma #LifeSciences #marketing #cdmo

Eli Lilly just did what no one thought possible - it beat Keytruda. Mounjaro + Zepbound (tirzepatide) pulled in $10.1B last quarter, topping Merck’s $8.1B from Keytruda. Total Q3 revenue? Up 54% to $17.6B - even with price cuts. When a weight-loss drug overtakes the world’s #1 cancer therapy, the message is clear: The next pharma arms race isn’t in oncology. It’s in metabolism. #EliLilly #GLP1 #Mounjaro #Zepbound #PharmaNews #MetabolicHealth #Biotech

Novartis just threw down $12B to go after muscle. They’re buying Avidity Biosciences - one of the few biotechs actually figuring out how to get RNA drugs into muscle instead of just the liver. It’s a big move, but it makes sense. Avidity’s chasing treatments for Duchenne and myotonic dystrophy - two brutal diseases with almost no real options. If their data holds up next year, this could be a turning point.

𝗙𝗼𝗿 𝗺𝗼𝗻𝘁𝗵𝘀, 𝗜 𝗸𝗲𝗽𝘁 𝗶𝘁 𝗽𝗿𝗶𝘃𝗮𝘁𝗲. Family knew. A few close friends. The emagine team. That was it. I didn’t tell clients - I didn’t want them thinking the business was in trouble. It wasn’t. I didn’t post on LinkedIn - I didn’t want pity. And honestly, I didn’t want people to see the “salesy guy,” the guy all over videos and social, and think, wow … he’s sick. But one day, hiding felt heavier than the diagnosis itself. When I finally shared my story, the response floored me - clients sending cards, notes, gifts, thoughtful messages. And this community … nearly 34,000 people, many I’ve never met, showing more kindness than I ever expected. It reminded me what real connection looks like. linkedin.com/pulse/why-i-fin…

𝗥𝗲𝗶𝗺𝗮𝗴𝗶𝗻𝗶𝗻𝗴 𝗠𝗲𝗻𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗖𝗮𝗿𝗲: 𝗕𝗲𝗵𝗶𝗻𝗱 𝘁𝗵𝗲 𝗟𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝘁𝗵𝗲 𝗧𝗥𝗜𝗣 𝗖𝗹𝗶𝗻𝗶𝗰𝘀 𝗮𝘁 𝗣𝘀𝘆𝗰𝗵𝗲𝗱𝗲𝗹𝗶𝗰 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 Some projects change you. This was one of them. When emagineHealth was asked to create the brand strategy, messaging, and website for the new Psychedelic Science Institute (PSI), I knew this was more than a creative assignment. It was about credibility in one of the most exciting - and misunderstood - frontiers of medicine. So we dove deep. We listened to patients who felt abandoned by traditional treatments. We studied the sentiment around psychedelics - equal parts hope, hype, and hesitation. And I came to one clear truth: before PSI could earn trust, it had to overcome stigma. Too many people still picture psychedelic therapy as a mystical retreat. PSI is the opposite: Born from two pioneers - PNI’s TRIP Center (Santa Monica) and the California Center for Psychedelic Therapy (Larchmont). Backed by a decade of neuroscience leadership, clinical trials across 10 Centers of Excellence, and thousands of supervised treatments. Led by internationally recognized clinician-scientists: Daniel F. Kelly, MD, Keith Heinzerling, MD, Brooke Balliett, LMFT, Micah Linton, Psy.D., and Gregory Kearns, MBA. Our team’s job was to shape a brand that could stand apart - rooted in science, yet human at its core. We built it around three principles: - Patient-Centricity - Patients remain in control with full understanding, consent, and the freedom to pause or opt out at any time. - Care emphasizes preparation, supervised dosing, and post-session integration within a “set and setting” model. Clarity No mysticism, no jargon. PSI communicates facts, education, and support to help patients make informed decisions and form realistic expectations. Diversity As one of the most active psychedelic trial and treatment sites in the US, PSI is deeply committed to inclusion. They proudly serve diverse populations, including members of the BIPOC and LGBTQIA+ communities. The new website reflects all of this: structured, trustworthy, and human - a digital home where science, safety, and compassion converge. Why did our team care so much? Because PSI’s work matters. They’re advancing safe, effective therapies for depression, anxiety, PTSD, addiction, bipolar disorder, and more. They’re training the next generation of clinicians. And they’re expanding access to communities too often left behind. For me, this wasn’t just brand strategy. It was about helping credible leaders in neuroscience and psychiatry bring their vision to the world. I couldn’t be prouder of the work - or of what PSI represents. Check it out: psychedelicsci.com/

🚨 𝗖𝗗𝗠𝗢 & 𝗖𝗥𝗢 𝗘𝘅𝗲𝗰𝘀: 𝗦𝘁𝗼𝗽 𝘄𝗵𝗮𝘁 𝘆𝗼𝘂’𝗿𝗲 𝗱𝗼𝗶𝗻𝗴. 𝗜𝗳 𝘆𝗼𝘂 𝗿𝗲𝗮𝗱 𝗻𝗼𝘁𝗵𝗶𝗻𝗴 𝗲𝗹𝘀𝗲 𝘁𝗼𝗱𝗮𝘆, 𝗿𝗲𝗮𝗱 𝘁𝗵𝗶𝘀. Because tomorrow morning, the way you think about your business needs to change. Your facilities? Table stakes. Your science? Table stakes. Your “capacity to scale”? Everyone says that. That biotech founder sitting across from you? They’re betting their entire life’s work on you. One drug. One shot. If you screw it up - bad data, weak CMC, sloppy GMP - it’s over for them. So ask yourself the only question that matters: 𝑾𝒐𝒖𝒍𝒅 𝒀𝑶𝑼 𝒃𝒖𝒚 𝒇𝒓𝒐𝒎 𝒚𝒐𝒖? Not in theory. Not “we’d be competitive.” I mean if your company held your one shot - would you trust yourself? If the answer isn’t a hard yes, your marketing, your leadership, and your story are failing you. This isn’t about polishing a brand. This is about survival. ☕ It’s Sunday. Drink your coffee. Then read this and let it hit you. By tomorrow morning, it should already be shaping your strategy.

𝗜 𝗵𝗮𝘃𝗲𝗻’𝘁 𝘀𝗵𝗮𝗿𝗲𝗱 𝘁𝗵𝗶𝘀 𝗽𝘂𝗯𝗹𝗶𝗰𝗹𝘆 𝘂𝗻𝘁𝗶𝗹 𝗻𝗼𝘄, 𝘀𝗼 𝘁𝗵𝗶𝘀 𝗽𝗼𝘀𝘁 𝗶𝘀 𝗻𝗼𝘁 𝗲𝗮𝘀𝘆 𝗳𝗼𝗿 𝗺𝗲. Last October, I was diagnosed with esophageal junction cancer. Thankfully, it was caught before it had spread. Since then, I’ve been through two phases of intensive chemo (FLOT and FOLFOX) and six weeks of daily radiation. The tumor has shrunk significantly. Now we’re evaluating whether surgery is possible - it’s complicated because of its proximity to a major artery. It’s been quite a year, to say the least. Why share this now? Because I believe in authenticity. Because being on this side of the healthcare equation has given me perspective I can’t keep to myself. And because if my story pushes even one person to get checked sooner, it’s worth it. Please - nobody needs to worry about me or about emagine. We’re possibly on track for our strongest year ever, and I’ve been more effective in my role through treatment than I’ve been in years. This is hell, yes - but it fuels me. I’ve never worked as hard as I am now - but it’s all by choice. I’m proud to say that we’ve built an agency and a team that doesn’t miss a beat when one of us has to deal with some things. In fact, everyone steps up even more. And that’s exactly what’s happened. We are stronger than we’ve ever been. I owe everything to my cofounder Brett Cohen, our EVP of Operations Christian Nolen, my big sis and VP of Biz Dev Dawn Gadless, and most of all, my wife Krystal Galewski. I couldn’t do this without them. My mom, my siblings, my extended family - plus every single member of the emagine team - words can’t even convey how much their strength and support has meant to me. I will keep fighting every day. And if pieces of my journey find their way into future posts, I hope you’ll take them as they’re intended - to inform, to connect, to inspire. Thank you for being here. Interacting with you all has been its own kind of immense therapy.